CART models using these 58 proteins as predictors showed a strong ability to differentiate between APOE ε4 carriers and noncarriers across each of the neurodegenerative disease groups (performance metrics > 0.85; Extended Data Table 2). This evidence concerns the gene APOE and neurodegenerative disease.